Abstract
Interventions that both improve outcomes and save costs are unusual, but the provision of lifesaving medications to survivors of myocardial infarction is one such example.1 In the past, physicians' poor compliance with evidence-based guidelines was a major reason for suboptimal use of such medications. Now, with help from the dissemination of quality metrics, cost-saving medications such as beta-blockers, aspirin, and angiotensin-converting–enzyme (ACE) inhibitors are nearly universally prescribed to eligible patients after myocardial infarction,2,3 so the focus has switched from physician prescribing to patient adherence. The concept of value-based insurance design,4 which is encouraged by the Patient Protection and Affordable . . .
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
